Annexon Reports Significant Progress with its Priority Progr

13.11.2023 - Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track for ...

Related Keywords

United States , Brisbane , Queensland , Australia , American , Sheryl Seapy , Chelcie Lister , American Society Of Nephrology Kidney Week , European Medicines Agency , Annexon Inc , Securities Exchange , Pivotal Program In Guillain Barr , Strategic Communications , Clinical Program Updates , Nasdaq , American Academy Of Ophthalmology , Global Regulatory Interactions Ongoing , Advance Phase , Resources Support Cash Runway , Douglas Love , Regulatory Progress , Geographic Atrophy , Priority Medicine , American Academy , Classical Pathway , Key Driver , Complement Activation , Active Lupus Nephritis , American Society , Kidney Week , Amyotrophic Lateral Sclerosis , Securities Act , Securities Exchange Act , Annual Report , Quarterly Reports , Private Securities Litigation Reform Act , Consolidated Statements , Annexon Chart , Nnexon Kurs , Nnexon Aktie ,